



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy
Pure Communications, Inc.
(949) 608-0841

Foundation Medicine to Present New Data on its Comprehensive Cancer Genomic Test at ASCO 2011 Annual Meeting

CAMBRIDGE, Mass. – May 19, 2011 – [Foundation Medicine, Inc.](#), a cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine care, today announced that it will present new data from its next-generation sequencing (NGS) based testing platform, at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2011, at McCormick Place in Chicago.

Jeffrey S. Ross, M.D., Cyrus Strong Merrill Professor & Chair, department of pathology & laboratory medicine, Albany Medical College, and interim head of pathology and molecular diagnostics at Foundation Medicine, will present a poster titled “Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues” (abstract number 10564) during the Tumor Biology general poster session from 8 a.m. to noon (CDT) on Monday, June 6, 2011.

“We are very excited to share new data with the oncology community that will highlight the potential clinical applications of Foundation Medicine’s comprehensive cancer genomic test,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. “These data demonstrate our ability to apply NGS to the small amounts of tumor tissue often present in routine formalin-fixed, paraffin embedded (FFPE) clinical specimens. We believe that our ability to provide physicians with comprehensive, accurate and timely test results from routine clinical specimens will help physicians make the most informed treatment recommendations and, in turn, significantly benefit cancer patients.”

About Foundation Medicine

Foundation Medicine is dedicated to the development of a comprehensive diagnostic test that improves cancer care by helping physicians personalize treatment for their patients. Foundation Medicine’s laboratory test is being designed to accommodate a broad landscape of cancer genome information and a growing repertoire of more targeted treatments and clinical research opportunities. Foundation Medicine’s test will assist physicians to make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patient’s unique cancer-associated alterations alongside publicly available scientific and medical information. The company’s founding advisors are world leaders in

genome technology, cancer biology and medical oncology; they, alongside clinicians, biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the company's website at www.foundationmedicine.com.

###